PureTech Health (LON:PRTC) Shares Down 9.2% - Time to Sell?

Key Points

• Shares fell 9.2% to GBX 126 on Tuesday, with 1,066,844 shares traded—about 15% below the average session volume.
• Financials show a negative P/E (-2.74) and market cap of £306.7M, with high debt-to-equity (6.33) but strong liquidity ratios (current 6.59, quick 2.51).
• PureTech is a clinical-stage biopharma developing microbiome-based immune therapies and products for neurological and metabolic disorders, including diagnostics, noninvasive neurostimulation, and oral weight-loss candidates.

PureTech Health plc (LON:PRTC - )'s share price traded down 9.2% on Tuesday . The company traded as low as GBX 126 and last traded at GBX 126. 1,066,844 shares traded hands during mid-day trading, a decline of 15% from the average session volume of 1,249,921 shares. The stock had previously closed at GBX 138.80.

PureTech Health Stock Performance

The company has a debt-to-equity ratio of 6.33, a current ratio of 6.59 and a quick ratio of 2.51. The stock has a market capitalization of £306.71 million, a PE ratio of -2.74 and a beta of 1.35. The stock has a 50 day moving average of GBX 121.85 and a two-hundred day moving average of GBX 125.88.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.